US equities |
META $630.56 ▲+0.00% MU $903.70 ▲+0.00% TSLA $391.62 ▲+0.00% NVDA $216.00 ▲+0.00% SPCX $146.90 ▲+0.00% SNDK $1,255.58 ▲+0.00% INTC $90.47 ▲+0.00% AMD $531.28 ▲+0.00%
FinancialContent

Articles published by Morphic Therapeutic

News headline image
Morphic to Participate in Jefferies Global Healthcare Conference
From Morphic Therapeutic
Via GlobeNewswire
Tickers MORF
News headline image
Morphic Demonstrates Novel Real-Time Visualization of Small Molecule α4β7 Inhibition of Gut-Trafficking Cells
From Morphic Therapeutic
Via GlobeNewswire
Tickers MORF
News headline image
Morphic to Participate in RBC Capital Markets Global Healthcare Conference
From Morphic Therapeutic
Via GlobeNewswire
Tickers MORF
News headline image
Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024
From Morphic Therapeutic
Via GlobeNewswire
Tickers MORF
News headline image
Morphic Appoints Dr. Simon Cooper as Chief Medical Officer
From Morphic Therapeutic
Via GlobeNewswire
Tickers MORF
News headline image
Morphic to Participate in March Investor Conferences
From Morphic Therapeutic
Via GlobeNewswire
Tickers MORF
News headline image
Morphic Announces Corporate Highlights and Financial Results for the Full Year 2023
From Morphic Therapeutic
Via GlobeNewswire
Tickers MORF
News headline image
Morphic to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Morphic Therapeutic
Via GlobeNewswire
Tickers MORF
News headline image
Morphic to Present at November Investor Conferences
From Morphic Therapeutic
Via GlobeNewswire
Tickers MORF
News headline image
Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2023
From Morphic Therapeutic
Via GlobeNewswire
Tickers MORF
News headline image
Morphic Therapeutic to Host Webcast to Present EMERALD-1 Full Data Set
From Morphic Therapeutic
Via GlobeNewswire
Tickers MORF
News headline image
Morphic Holdings Announces CEO Dr. Praveen Tipirneni to Take Temporary Medical Leave of Absence
From Morphic Therapeutic
Via GlobeNewswire
Tickers MORF
News headline image
Morphic to Present Positive EMERALD-1 Phase 2a Data for MORF-057 in Patients with Moderate to Severe Ulcerative Colitis in Abstract for UEGW 2023
From Morphic Therapeutic
Via GlobeNewswire
Tickers MORF
News headline image
Morphic Announces Participation in 2023 Wells Fargo Healthcare Conference
From Morphic Therapeutic
Via GlobeNewswire
Tickers MORF
News headline image
Morphic to Present at the Canaccord Genuity 43rd Annual Growth Conference
From Morphic Therapeutic
Via GlobeNewswire
Tickers MORF
News headline image
Morphic Announces Corporate Highlights and Financial Results for the Second Quarter 2023
From Morphic Therapeutic
Via GlobeNewswire
Tickers MORF
News headline image
Morphic to Present at the Jefferies Global Healthcare Conference
From Morphic Therapeutic
Via GlobeNewswire
Tickers MORF
News headline image
Morphic to Present at 2023 RBC Capital Markets Global Healthcare Conference
From Morphic Therapeutic
Via GlobeNewswire
Tickers MORF
News headline image
Morphic Presents New Biomarker Data at DDW 2023 Supporting MORF-057 Program in Ulcerative Colitis
From Morphic Therapeutic
Via GlobeNewswire
Tickers MORF
News headline image
Morphic Therapeutic Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Morphic Therapeutic
Via GlobeNewswire
Tickers MORF
News headline image
Morphic Therapeutic Announces Pricing of $240.0 Million Public Offering
From Morphic Therapeutic
Via GlobeNewswire
Tickers MORF
News headline image
Morphic Therapeutic Announces Proposed Public Offering
From Morphic Therapeutic
Via GlobeNewswire
Tickers MORF
News headline image
Morphic Reports Positive Topline Results of the EMERALD-1 UC Main Cohort; Orally Administered MORF-057 Achieves Primary Endpoint and Demonstrates Clinically Meaningful Improvements Across Secondary and Exploratory Measures
From Morphic Therapeutic
Via GlobeNewswire
Tickers MORF
News headline image
Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2023
From Morphic Therapeutic
Via GlobeNewswire
Tickers MORF
News headline image
Morphic Therapeutic to Host EMERALD-1 Topline Results Call on April 25, 2023
From Morphic Therapeutic
Via GlobeNewswire
Tickers MORF
News headline image
Morphic to Present at TD Cowen 43rd Annual Health Care Conference
From Morphic Therapeutic
Via GlobeNewswire
Tickers MORF
News headline image
Morphic Announces Corporate Highlights and Financial Results for the Full Year 2022
From Morphic Therapeutic
Via GlobeNewswire
Tickers MORF
News headline image
Morphic to Present at SVB Leerink Global Healthcare Conference
From Morphic Therapeutic
Via GlobeNewswire
Tickers MORF
News headline image
Morphic to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Morphic Therapeutic
Via GlobeNewswire
Tickers MORF
News headline image
Morphic Announces Initiation of EMERALD-2 Phase 2b Clinical Trial of MORF-057 in Patients with Moderate-to-Severe Ulcerative Colitis
From Morphic Therapeutic
Via GlobeNewswire
Tickers MORF